Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 33 clinical trials
Targeted Therapy and Avelumab in Merkel Cell Carcinoma

type of peptide receptor radionuclide therapy; PRRT) or external beam radiation therapy (EBRT) in patients with metastatic Merkel cell carcinoma (mMCC).

  • 0 views
  • 29 Apr, 2021
  • 6 locations
Study of PRRT in Metastatic World Health Organization (WHO) Grade 1 or 2 SSTR Positive GEP-NET Who Are Candidates for Cytoreductive Surgery

The purpose of this study is to learn about the feasibility and safety of using Peptide Receptor Radionuclide Therapy (PRRT) before and after surgical removal of a tumor. PRRT treatment is based

  • 0 views
  • 27 Apr, 2021
  • 1 location
Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor

somatostatin receptors, is an internal vectorized radiotherapy using Lu-177, an ideal radionuclide for peptide radionuclide therapy. In NETTER-1 phase III randomized clinical trial, Lu-177 Dotatate proved its

  • 0 views
  • 26 Jan, 2021
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in

edotreotide
everolimus
progressive disease
somatostatin
radionuclide therapy
  • 220 views
  • 22 Sep, 2021
  • 84 locations
Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012

]ICF01012 ). The [131I]ICF01012 is a targeted radionuclide therapy with a high affinity for melanin.

melanoma skin
malignant melanoma of skin
measurable disease
metastatic melanoma
  • 4 views
  • 31 Jan, 2021
  • 2 locations
67Cu-SARTATE Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Relapsed Refractory Neuroblastoma

The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.

renal function
neutrophil count
combination chemotherapy
refractory neuroblastoma
platelet count
  • 0 views
  • 14 Aug, 2021
  • 5 locations
HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody

radionuclide therapy in Breast Cancer. The SPECT/CT results will compare with the existing gold standard " HER2 expression detection" by biopsy tissue immunohistochemistry (IHC) and/or Fluorescence in Situ

  • 0 views
  • 28 Jan, 2021
  • 1 location
Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)

The rationale behind the purpose of this study lays on: the evidence that PRRT could represent a valuable treatment for the majority of patients with neuroendocrine tumor (NET) in disease progression, operated or inoperable, presenting lesions expressing somatostatin receptors and for which standard treatments are not already available; the current …

  • 1 views
  • 18 Mar, 2021
  • 1 location
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

This pilot phase II trial studies how effective pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy are at treating patients with well-differentiated neuroendocrine

dotatate
tetraxetan
international normalized ratio
somatostatin
neutrophil count
  • 15 views
  • 03 Sep, 2021
  • 1 location
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

The NET-PACS trial is a Prospective Assessment of patients with neuroendocrine tumors and current or prior history of Carcinoid Syndrome or diarrhea undergoing peptide receptor radionuclide

  • 0 views
  • 25 Apr, 2021
  • 1 location